Compare Alcon AG (ALC) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Freeport-McMoRan Inc — how do they compare? Alcon AG trades at $73.45 (market cap $35.29B), while Freeport-McMoRan Inc trades at $66.67 (market cap $96.91B). The key difference: Freeport-McMoRan Inc is far larger — about 2.7× Alcon AG's market cap, and Freeport-McMoRan Inc pays the higher dividend (0.87%). Which is the better fit depends on your goals.
| ALC | FCX | |
|---|---|---|
Market Cap | $35.29B | $96.91B |
Sector | Health | Basic Materials |
52-Week High | $90.12 | $71.73 |
52-Week Low | $62.02 | $35.34 |
Enterprise Value | $39.13B | $103.19B |
Dividend Yield | 0.49% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.52, down 2.43% on the day, with a bullish technical signal from moving averages. Recent Q2 2026 earnings beat estimates, and the company raised its 2026 profitability outlook. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. The stock is supported by strong analyst consensus, with a price target of $85.85.
Outlook is positive due to earnings beats and raised guidance, but high P/E of 56.17 poses valuation risk. Competition and margin pressures are key concerns. Institutional interest is rising, with Bill Ackman's new position noted in August 2026 news.
FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.
The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
